252340-85-5

Upstream product

• 369-34-6 3,4-difluoronitrobenzene 
• 252340-74-2 5-Benzyloxycarbonylamino-2-(4-methyl-imidazol-1-yl)fluorobenzene 
• 252337-29-4 3-fluoro-4-(4-methyl-imidazol-1-yl)nitrobenzene 
• 252340-70-8 5-Amino-2-(4-methyl-imidazol-1-yl)fluorobenzene 
• 252340-78-6 (5R)-3-[3'-fluoro-4'-(4''-methyl-1''H-imidazol-1-yl)phenyl]-5-(hydroxymethyl)-oxazolidin-2-one 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 264600-54-6 3-(4(4-methylimidazol-1-yl)-3-fluorophenyl)-5(R)-(N-(t-butoxycarbonyl)isoxazol-3-yl-aminomethyl)oxazolidin-2-one 
• 591232-47-2 (5S)-[N-3-(3'-fluoro-4'-(4-methyl-1(H)-imidazolyl)phenyl)-2-oxo-5-oxazolidinyl]methylamine 
• 591232-48-3 (5R)-5-(azidomethyl)-3-[3-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-1,3-oxazolidin-2-one 

Relevant academic research and scientific papers

A method for the prevention or treatment of mycobacterial diseases

Disclosed in the present invention is a drug for preventing or treating mycobacterial diseases. In particular, disclosed is the use of a compound represented by the following general formula (I) or pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs thereof in preparing drugs for preventing or treating mycobacterial diseases, providing a new way for the prevention and treatment of tuberculosis and the like.

HETEROCYCLYLAMINOMETHYLOXAZOLIDINONES AS ANTIBACTERIALS

Compounds of formula (I) or a pharmaceutically-acceptable salt, or an in-vivo hydrolysable ester thereof, wherein, for example,HET is an optionally substituted C-linked 5-membered heteroaryl ring containing 2 to 4 heteroatoms independently selected from N

Oxazolidinone derivatives with antibiotic activity

Compounds of the formula (I), or a pharmaceutically acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein HET is an N-linked 5-membered heteroaryl ring, optionally substituted on a C atom by an oxo or thioxo group; and/or by 1 or 2 (1-4C)alkyl groups; and/or on an available nitrogen atom by (1-4C)alkyl; or HET is an N-linked 6-membered heteroaryl ring containing up to three nitrogen heteroatoms in total, optionally substituted on a C atom as above; Q is selected from, for example, Q1 R2 and R3 are independently hydrogen or fluoro; T is selected from a range of groups, for example, of formula (TC5) wherein Rc is, for example, R13CO—, R13SO2— or R13CS—; wherein R13 is, for example, optionally substituted (1-10C)alkyl or R14C(O)O(1-6C)alkyl wherein R14 is optionally substituted (1-10C)alkyl; are useful as antibacterial agents; and processes for their manufacture and pharmaceutical compositions containing them are described.